Skip to Content
Diagnosed with PsA? Learn about biologics >

Dexamethasone Pregnancy and Breastfeeding Warnings

Dexamethasone is also known as: Adrenocot, Adrenocot LA, Baycadron, Dalalone, Dalalone DP, Dalalone LA, De-Sone LA, Decadron, Decadron Phosphate, Injectable, Decadron-LA, Decaject, Decaject LA, Dexacen-4, Dexacort Phosphate in Respihaler, Dexacort-LA, Dexamethasone Intensol, Dexasone, Dexone, Dexpak Taperpak, Hexadrol, LoCort, Solurex, Solurex LA, Zema Pak, Zonacort

Dexamethasone Pregnancy Warnings

This drug readily crosses the placenta. Teratogenicity including increased incidence of cleft palate have occurred in animal studies, however, the relevance to human has been questioned. Reduced placental and birth weight have been recorded in animals and humans after long term treatment. There is the possibility of adrenal cortex suppression in the newborn with long term use in the mother; however, the short term use of corticosteroids antepartum for the prevention of respiratory distress syndrome does not seem to pose a risk to the fetus or the newborn infant. Maternal pulmonary edema has been reported with inhibition of uterine contractions and fluid overload. There are no adequate and well controlled studies in pregnant women. Increases and decreases in sperm motility and number of sperm have been observed in some patients. AU TGA pregnancy category A: Drugs which have been taken by a large number of pregnant women and women of childbearing age without any proven increase in the frequency of malformations or other direct or indirect harmful effects on the fetus having been observed. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Benefit should outweigh risk AU TGA pregnancy category: A (oral); C (parenteral) US FDA pregnancy category: C Comments: -Observe for signs and symptoms of hypoadrenalism in infants exposed in utero. -The short-term use of corticosteroids antepartum for the prevention of respiratory distress syndrome does not seem to pose a risk to the fetus or newborn infant.

See references

Dexamethasone Breastfeeding Warnings

Corticosteroids appear in breast milk in low amounts; specific information on this drug is unknown. Theoretically, its presence in breast milk could suppress growth, interfere with endogenous corticosteroid production, or cause other unwanted effects in breast fed babies. It is presumed that breastfed infants of mothers taking high doses of systemic corticosteroids for prolonged periods of time may have some degree of adrenal suppression.

Benefit should outweigh risk Excreted into human milk: Unknown Comments: Mothers receiving pharmacologic doses should generally avoid breastfeeding; single doses and local use are generally compatible with breastfeeding.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. Dexamethasone (dexamethasone)." Par Pharmaceutical Inc (formerly Qualitest Pharmaceuticals Inc), Huntsville, AL.
  4. "Product Information. Dexamethasone Sodium Phosphate (dexamethasone)." West-Ward Pharmaceutical Corporation, Eatontown, NJ.

References for breastfeeding information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
  4. "Product Information. Dexamethasone (dexamethasone)." Par Pharmaceutical Inc (formerly Qualitest Pharmaceuticals Inc), Huntsville, AL.
  5. Department of Adolescent and Child Health and Development. UNICEF. World Health Organization "Breastfeeding and maternal medication: recommendations for drugs in the eleventh Who model list of essential drugs. Available from: URL: http://whqlibdoc.who.int/hq/2002/55732.pdf?ua=1" ([2003]):
  6. "Product Information. Dexamethasone Sodium Phosphate (dexamethasone)." West-Ward Pharmaceutical Corporation, Eatontown, NJ.

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide